Pharmigene, Inc.
Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test… Read more
Pharmigene, Inc. (7595) - Total Assets
Latest total assets as of June 2025: NT$964.12 Million TWD
Based on the latest financial reports, Pharmigene, Inc. (7595) holds total assets worth NT$964.12 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharmigene, Inc. - Total Assets Trend (2019–2024)
This chart illustrates how Pharmigene, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pharmigene, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Pharmigene, Inc.'s total assets of NT$964.12 Million consist of 25.0% current assets and 75.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 9.2% |
| Accounts Receivable | NT$13.32 Million | 1.3% |
| Inventory | NT$53.68 Million | 5.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$13.44 Million | 1.3% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Pharmigene, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharmigene, Inc.'s current assets represent 25.0% of total assets in 2024, a decrease from 75.4% in 2019.
- Cash Position: Cash and equivalents constituted 9.2% of total assets in 2024, down from 26.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 4.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 5.4% of total assets.
Pharmigene, Inc. Competitors by Total Assets
Key competitors of Pharmigene, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Pharmigene, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Pharmigene, Inc. generates 0.12x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Pharmigene, Inc. is currently not profitable relative to its asset base.
Pharmigene, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.46 | 6.13 | 9.31 |
| Quick Ratio | 1.77 | 5.24 | 8.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$105.62 Million | NT$ 186.77 Million | NT$ 208.36 Million |
Pharmigene, Inc. - Advanced Valuation Insights
This section examines the relationship between Pharmigene, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.21 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -4.2% |
| Total Assets | NT$1.00 Billion |
| Market Capitalization | $10.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pharmigene, Inc.'s assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Pharmigene, Inc.'s assets decreased by 4.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Pharmigene, Inc. (2019–2024)
The table below shows the annual total assets of Pharmigene, Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.00 Billion | -4.18% |
| 2023-12-31 | NT$1.05 Billion | +172.45% |
| 2022-12-31 | NT$384.27 Million | -8.32% |
| 2021-12-31 | NT$419.12 Million | -6.84% |
| 2020-12-31 | NT$449.91 Million | +161.23% |
| 2019-12-31 | NT$172.23 Million | -- |